Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: a Multicenter RCT

• Status: RECRUITING
• Trial end date: 2027-12-31

Summary

The goal of this clinical trial is to evaluate whether Finerenone and Empagliflozin, either alone or in combination, can delay the progression of renal function decline in patients at high risk for chronic kidney disease (CKD) following radical nephrectomy for renal cell carcinoma (RCC). It will also assess the safety of these treatments.The main questions it aims to answer are:

1. Does Finerenone and Empagliflozin, alone or in combination, slow the progression of renal function decline in high-risk CKD patients after RCC surgery?

2. What are the safety profiles of Finerenone and Empagliflozin in this patient population?

Researchers will compare the treatment groups (Finerenone and Empagliflozin) to a blank control group (no drug) to determine if the treatments effectively delay renal function decline.

Participants will:

1. Take either Finerenone and Empagliflozin (alone or in combination) or a blank control every day for 1 years.

2. Visit the clinic once every 3 months for checkups and tests.

3. Track their eGFR and other kidney function markers regularly.

4. Keep a diary to record any adverse events or changes in their health condition during the study.

• Phase: PHASE2

Details

• Lead Sponsor: Jinling Hospital, China
• Collaborators: Qilu Hospital of Shandong University; The Affiliated Hospital of Xuzhou Medical University; The First Affiliated Hospital with Nanjing Medical University; Yantai Yuhuangding Hospital
• Treatments: empagliflozin; finerenone